Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Pacira BioSciences, Inc.’s reported figures.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
FAQ
- What is Pacira BioSciences, Inc.'s EBITDA?
- Pacira BioSciences, Inc. (PCRX) reported EBITDA of $28.23M in Q1 2026.
- How has Pacira BioSciences, Inc.'s EBITDA changed year-over-year?
- Pacira BioSciences, Inc.'s EBITDA increased by 21.9% year-over-year, from $23.16M to $28.23M.
- What is the long-term trend for Pacira BioSciences, Inc.'s EBITDA?
- Over 2 years (2021 to 2025), Pacira BioSciences, Inc.'s EBITDA has grown at a -3.5% compound annual growth rate (CAGR), from $118.47M to $110.21M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Pacira BioSciences, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude